Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of initiating LCZ696 in heart failure: conservative vs condensed titration
2013-001835-33Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan in chronic heart failure (CHF) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Novartis. Primary endpoint: Percentage of patients experiencing specified adverse events. Started Aug 2013; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2013-001835-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001835-33.